US2007179188A1PendingUtilityA1
Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
Est. expiryFeb 18, 2024(expired)· nominal 20-yr term from priority
Inventors:Louise EdwardsMethvin IsaacMartin JohanssonAnnika KersJohan MalmbergDonald McleodAlexander MinidisKarin StaafAbdelmalik SlassiTomislav StefanacThomas StormannDavid WensboTao XinJalaj Arora
A61P 9/00A61P 35/00A61P 9/10A61P 3/08A61P 43/00A61P 27/06A61P 25/16A61P 29/00A61P 25/08A61P 25/04A61P 25/22A61P 25/06A61P 27/02A61P 25/28A61P 25/24A61P 25/00A61P 25/30A61P 25/18A61P 1/00A61P 21/02A61P 19/02A61P 19/06A61P 15/00C07D 487/04C07D 413/12C07D 413/14C07D 413/06
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to new compounds of formula (I), to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
Claims
exact text as granted — not AI-modified1 . A compound, or a pharmaceutically acceptable salt thereof, selected from the up consisting of the compounds set forth in the following table:
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
2 . A pharmaceutical formulation comprising as an active ingredient a therapeutically effective amount of a compound according to claim 1 in association with one or more pharmaceutically acceptable diluents, excipients and/or inert carriers.
3 . The pharmaceutical formulation according to claim 2 , for use in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
4 . A compound according to claim 1 for use in therapy.
5 . The compound according to claim 1 , for use in prevention and/or treatment of mGluR5 receptor-mediated disorders.
6 . The compound according to claim 5 , wherein the disorder is a neurological disorder.
7 . The compound according to claim 5 , wherein the disorder is a psychiatric disorder.
8 . The compound according to claim 5 , wherein the disorder is selected from chronic and acute pain disorders.
9 . The compound according to claim 5 , wherein the disorder is a gastrointestinal disorder.
10 . The compound according to claim 5 , wherein the disorder is selected from the group consisting of Alzheimer's disease, senile dementia, AIDS-induced dementia, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's Chorea, migraine, epilepsy, schizophrenia, depression, anxiety, acute anxiety, obsessive compulsive disorder, opthalmological disorders, diabetic retinopathies, glaucoma, auditory neuropathic disorders, chemotherapy induced neuropathies, post-herpetic neuralgia and trigeminal neuralgia, tolerance, dependency, addiction and craving disorders, neurodevelopmental disorders, autism, mental retardation, schizophrenia, Down's Syndrome, pain related to migraine, inflammatory pain, neuropathic pain disorders, arthritis and rheumatitiod diseases, low back pain, post-operative pain, pain associated with angina, renal and billiary colic, menstruation, migraine gout, stroke, head trauma, anoxic and ischemic injuries, hypoglycemia, cardiovascular diseases, GERD, and epilepsy.
11 . The use of a compound according to claim 1 in the manufacture of a medicament for the use in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
12 . A method of prevention and/or treatment of mGluR5 receptor-mediated disorders, comprising administering to a mammal in need of such prevention and/or treatment a therapeutically effective amount of a compound according to claim 1 .
13 . The method according to claim 12 , wherein the disorder is a neurological disorder.
14 . The method according to claim 12 , wherein the disorder is a psychiatric disorder.
15 . The method according to claim 12 , wherein the disorder is selected from chronic and acute pain disorders.
16 . The method according to claim 12 , wherein the disorder is a gastrointestinal disorder.
17 . The method according to claim 12 , wherein the disorder is selected from the group consisting of Alzheimer's disease, senile dementia, AIDS-induced dementia, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's Chorea, migraine, epilepsy, schizophrenia, depression, anxiety, acute anxiety, obsessive compulsive disorder, opthalmological disorders, diabetic retinopathies, glaucoma, auditory neuropathic disorders, chemotherapy induced neuropathies, post-herpetic neuralgia and trigeminal neuralgia, tolerance, dependency, addiction and craving disorders, neurodevelopmental disorders, autism, mental retardation, schizophrenia, Down's Syndrome, pain related to migraine, inflammatory pain, neuropathic pain disorders, arthritis and rheumatitiod diseases, low back pain, post-operative pain, pain associated with angina, renal and billiary colic, menstruation, migraine gout, stroke, head trauma, anoxic and ischemic injuries, hypoglycemia, cardiovascular diseases and epilepsy.
18 . A method for inhibiting the activation of mGluR5 receptors, comprising treating a cell containing said receptor with an effective amount of a compound according to claim 1.Join the waitlist — get patent alerts
Track US2007179188A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.